Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule

Bis-benzimidazole anticancer agents: targeting human tumour helicases.

Anti-cancer drug design·1999

Antihelicase action of CI-958, a new drug for prostate cancer.

Cancer chemotherapy and pharmacology·1998

Anthracycline antibiotic blockade of SV40 T antigen helicase action.

Biochemical pharmacology·1998

Antihelicase action of DNA-binding anticancer agents: relationship to guanosine-cytidine intercalator binding.

Molecular pharmacology·1993

A phase II trial of CI-921 in advanced malignancies.

Investigational new drugs·1992

Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1992

Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia.

Cancer·2026

Current challenges and emerging therapeutic strategies in lung cancer care: Insights from Bridging the Gaps 2025.

Cancer·2026

Progression-free survival and overall survival in the first-line treatment of BRCA wild-type advanced epithelial ovarian cancer: An analysis of patient-level data pooled from historical clinical trials.

Cancer·2026

Trends in sociodemographic factors associated with human papillomavirus vaccine hesitancy in the United States: 2010-2022.

Cancer·2026

External validation of the NADIR model for early prostate-specific antigen response prediction in enzalutamide-treated metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES trial.

Cancer·2026

Progression-free survival and objective response rate as a surrogate end point for overall survival in metastatic renal cell carcinoma: A systematic review and meta-analysis.

Cancer·2026

[Sacituzumab govitecan in a patient with early bone recurrence of triple-negative breast cancer refractory to first-line chemotherapy.]

Recenti progressi in medicina·2026

Quercetin Attenuates Cisplatin-Induced Nephrotoxicity While Enhancing Antitumor Efficacy in Gastric Cancer via Cell Type-Specific Modulation of the ERK1/2 Pathway.

Journal of biochemical and molecular toxicology·2026

Gedatolisib for the treatment of hormone receptor-positive/HER2-negative advanced breast cancer: a European perspective.

Future oncology (London, England)·2026

[Impact of anesthesia type on results of carotid endarterectomy: analytical review of randomized clinical trials].

Khirurgiia·2026

Stereotactic Ablative Body Radiotherapy Versus Microwave Ablation for the Treatment of Early-Stage Hepatocellular Carcinoma.

Journal of medical imaging and radiation oncology·2026

Postoperative Management of Direct Oral Anticoagulants After Elective Spine Surgery: When Can These Drugs be Safely Resumed?

Clinical spine surgery·2026

Related Experiment Videos

Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule

Related Concept Videos

Bis-benzimidazole anticancer agents: targeting human tumour helicases.

Antihelicase action of CI-958, a new drug for prostate cancer.

Anthracycline antibiotic blockade of SV40 T antigen helicase action.

Antihelicase action of DNA-binding anticancer agents: relationship to guanosine-cytidine intercalator binding.

A phase II trial of CI-921 in advanced malignancies.

Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma.

Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia.

Current challenges and emerging therapeutic strategies in lung cancer care: Insights from Bridging the Gaps 2025.

Progression-free survival and overall survival in the first-line treatment of BRCA wild-type advanced epithelial ovarian cancer: An analysis of patient-level data pooled from historical clinical trials.

Trends in sociodemographic factors associated with human papillomavirus vaccine hesitancy in the United States: 2010-2022.

External validation of the NADIR model for early prostate-specific antigen response prediction in enzalutamide-treated metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES trial.

Progression-free survival and objective response rate as a surrogate end point for overall survival in metastatic renal cell carcinoma: A systematic review and meta-analysis.

[Sacituzumab govitecan in a patient with early bone recurrence of triple-negative breast cancer refractory to first-line chemotherapy.]

Quercetin Attenuates Cisplatin-Induced Nephrotoxicity While Enhancing Antitumor Efficacy in Gastric Cancer via Cell Type-Specific Modulation of the ERK1/2 Pathway.

Gedatolisib for the treatment of hormone receptor-positive/HER2-negative advanced breast cancer: a European perspective.

[Impact of anesthesia type on results of carotid endarterectomy: analytical review of randomized clinical trials].

Stereotactic Ablative Body Radiotherapy Versus Microwave Ablation for the Treatment of Early-Stage Hepatocellular Carcinoma.

Postoperative Management of Direct Oral Anticoagulants After Elective Spine Surgery: When Can These Drugs be Safely Resumed?

Related Experiment Videos

Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule

Related Concept Videos

Related Articles